Cerenome, Inc.
corporate_fare Company Profile
Cerenome, Inc. (NASDAQ:CNSY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for CNSY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 8/10, with 4 rated 8 or above. Recent SEC coverage for CNSY spans 8-K, 10-Q.
Recent high-impact activity:
- Cerenome Reports Interim ReSPECT-LM Data: No Dose-Limiting Toxicity in First 10 Patients
- Cerenome Posts First $0.7M Diagnostic Revenue but Cash Drops to $4.9M
- Cerenome 10-Q: Going Concern Warning, Nasdaq Equity Deficiency After $8.7M Q3 Loss
- Cerenome Posts First Diagnostic Revenue but Cash Falls to $4.9M
- Aetna National Contract Adds 26M Members to CNSide Payer Footprint
Financial Snapshot
Short Interest & Short Volume
14.87 days to coverFINRA reported short interest of 844,013 shares in CNSY as of the October 30, 2026 settlement, a 7.9% increase from the prior period — about 14.9 days to cover at its recent average daily volume. On November 20, 2026, 61.2% of CNSY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CNSY, detected from its recent SEC filings · based on capital-structure filings through 2026-09-10.
Convertible Note Financing Terms · Conversion Price and Dilution Risk
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →